1,258 reports of this reaction
3.2% of all RIVASTIGMINE reports
#4 most reported adverse reaction
CONFUSIONAL STATE is the #4 most commonly reported adverse reaction for RIVASTIGMINE, manufactured by Sandoz Inc. There are 1,258 FDA adverse event reports linking RIVASTIGMINE to CONFUSIONAL STATE. This represents approximately 3.2% of all 39,624 adverse event reports for this drug.
Patients taking RIVASTIGMINE who experience confusional state should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONFUSIONAL STATE is moderately reported among RIVASTIGMINE users, representing a notable but not dominant share of adverse events.
In addition to confusional state, the following adverse reactions have been reported for RIVASTIGMINE:
The following drugs have also been linked to confusional state in FDA adverse event reports:
CONFUSIONAL STATE has been reported as an adverse event in 1,258 FDA reports for RIVASTIGMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONFUSIONAL STATE accounts for approximately 3.2% of all adverse event reports for RIVASTIGMINE, making it a notable side effect.
If you experience confusional state while taking RIVASTIGMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.